CLINICAL_TRIALS trial_result · 2021-09-02

Clinical Trial Update: A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder [Phase 2]

Phase 2 safety and efficacy study of Janssen's JNJ-42165279 in social anxiety disorder has completed, with results posted on 2021-09-02.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Janssen Research & Development, LLC | Conditions: Phobic Disorders | Phase 2 | Status: COMPLETED | Results posted: 2021-09-02